ArticleNeurology(R) neuroimmunology & neuroinflammation2016
Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Integrin β1 Demarks Precursors of Brain-Residing Antibody-Secreting Cells in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumab.iScience · 2025Article
- Review
- T-bet+ CXCR3+ B cells drive hyperreactive B-T cell interactions in multiple sclerosis.Cell reports. Medicine · 2025Article
- Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation.Frontiers in cellular neuroscience · 2024Review
- Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells.Neurology and therapy · 2023Article
- GPR43 stimulation on TCRαβJournal of neuroinflammation · 2023Article
- Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis.Science advances · 2023Article
- High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis.Frontiers in neurology · 2022Article
- Dopaminergic stimulation leads B-cell infiltration into the central nervous system upon autoimmunity.Journal of neuroinflammation · 2021Article
- Mass Cytometry of CSF Identifies an MS-Associated B-cell Population.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Decreased Neurofilament L Chain Levels in Cerebrospinal Fluid and Tolerogenic Plasmacytoid Dendritic Cells in Natalizumab-Treated Multiple Sclerosis Patients - Brief Research Report.Frontiers in cellular neuroscience · 2021Article
- The role of B cells in the immunopathogenesis of multiple sclerosis.Immunology · 2020Review
- Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.International journal of molecular sciences · 2020Review
- Article
- Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients.Journal of neuroinflammation · 2019Article
- Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis.Annals of neurology · 2019Article
- Dissecting Integrin Expression and Function on Memory B Cells in Mice and Humans in Autoimmunity.Frontiers in immunology · 2019Article
- Reassessing B cell contributions in multiple sclerosis.Nature immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the effects of natalizumab treatment on subgroups of circulating peripheral blood B cell populations.
methodsWe studied the proportions and absolute numbers of CD19
resultsProportions of B cells and CD10
conclusionsThe rapid and persistent increase in circulating CXCR3-expressing B cells in response to natalizumab treatment possibly reflects the relevance of this chemokine receptor in controlling migration of B cells into the CNS in humans in vivo.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.